Clinical Trials Directory

Trials / Conditions / Lupus Nephritis (LN)

Lupus Nephritis (LN)

27 registered clinical trials studyying Lupus Nephritis (LN)25 currently recruiting.

StatusTrialSponsorPhase
RecruitingSafety and Efficacy of ONT01 in Lupus
NCT07107659
Hospital for Special Surgery, New YorkEARLY_Phase 1
Not Yet RecruitingC-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease
NCT06935474
AbelZeta Inc.Phase 1 / Phase 2
Not Yet RecruitingEfficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
NCT07535138
Air Force Military Medical University, ChinaEARLY_Phase 1
RecruitingA Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE
NCT07491900
Hinge BioPhase 1
Not Yet RecruitingEfficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus
NCT07364396
Curocell Inc.Phase 1 / Phase 2
Not Yet RecruitingDapagliflozin in Active Lupus Nephritis
NCT07323524
Brigham and Women's HospitalPhase 4
Not Yet RecruitingBCMA-CD19 cCAR T for the Treatment of Refractory Lupus
NCT07328581
iCell Gene TherapeuticsPhase 1 / Phase 2
RecruitingDose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis
NCT06975787
Regeneron PharmaceuticalsPhase 1
RecruitingThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephri
NCT07340463
Nanjing University School of MedicinePhase 2
RecruitingAn Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07236762
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingStudy to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
NCT07363460
Haisco Pharmaceutical Group Co., Ltd.Phase 2
Not Yet RecruitingThe Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis
NCT07130448
Assiut University
Not Yet RecruitingSGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated
NCT07035834
Federico II UniversityPhase 4
RecruitingA Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
NCT07123519
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingA Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combin
NCT07038382
Shanghai Henlius BiotechPhase 2
RecruitingA Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07104721
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
Not Yet RecruitingMSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
NCT07000292
Shanghai Changzheng HospitalPhase 1 / Phase 2
RecruitingCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
NCT06839976
Children's Hospital of PhiladelphiaPhase 1 / Phase 2
RecruitingA Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
NCT06943937
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingEquecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NCT06902844
Tongji HospitalN/A
Not Yet RecruitingUrinary Congophilia as an Indicator of Activity of Lupus Nephritis
NCT06654024
Assiut University
RecruitingAnti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514
Beijing GoBroad HospitalPhase 1 / Phase 2
Not Yet RecruitingRenal Survival in Patients with Lupus Nephritis
NCT06588192
Assiut University
WithdrawnA Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN
NCT06419205
Q32 Bio Inc.Phase 2
WithdrawnAtacicept in Subjects With Active Lupus Nephritis (COMPASS)
NCT05609812
Vera Therapeutics, Inc.Phase 3
RecruitingResearch Accelerated by You Lupus Registry
NCT06927219
Lupus Foundation of America
RecruitingHigh Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)
NCT06682507
First Affiliated Hospital, Sun Yat-Sen University